Lupron Lawsuit: Settlements, Injury Claims, and Defense Verdicts

Lawsuits involving Lupron fall into two very different categories. The pricing-fraud cases were the big wins: TAP Pharmaceutical Products paid $875 million to the federal government in 2001 after pleading guilty to a criminal conspiracy, and a follow-on class action settled for $150 million in 2005 to repay private insurers and patients who had been overcharged.¹² Personal injury suits brought by patients who say Lupron caused lasting bone, joint, and neurological damage are the other story: they have largely lost, either at trial or on procedural grounds like the statute of limitations.

The $875 Million Federal Settlement

On October 3, 2001, TAP Pharmaceutical Products, a joint venture between Abbott Laboratories and Takeda Pharmaceutical Company, agreed to pay $875 million to resolve federal criminal charges and civil fraud claims. It was the largest health care fraud settlement of its kind at the time.¹

The scheme exploited how Medicare reimburses for drugs. TAP reported an inflated Average Wholesale Price for Lupron while quietly selling it to doctors at steep discounts. The gap between what physicians paid and what Medicare reimbursed, known as the “spread,” became a marketing pitch to steer doctors toward Lupron over cheaper alternatives.¹ TAP also gave doctors outright kickbacks: free samples that were then billed to Medicare, trips to golf and ski resorts, medical equipment, “educational grants” worth up to $100,000, and debt forgiveness.³

The breakdown: TAP pleaded guilty to conspiring to violate the Prescription Drug Marketing Act and paid a $290 million criminal fine. The civil piece included $559.5 million to the federal government under the False Claims Act and $25.5 million to all fifty states and the District of Columbia for Medicaid pricing violations. The case was triggered by Douglas Durand, a former TAP vice president of sales, who filed a False Claims Act suit in 1996 after leaving the company.¹

The $150 Million Class Action for Insurers and Patients

The federal settlement compensated public programs, not private payers. Insurers and individuals who had overpaid for Lupron pursued their own claims, consolidated as In re: Lupron Marketing and Sales Practices Litigation, MDL No. 1430, in the U.S. District Court for the District of Massachusetts.⁴

In December 2004, TAP agreed to pay $150 million to settle without admitting wrongdoing.² The settlement class covered anyone who bought Lupron at a price tied to the inflated Average Wholesale Price between January 1, 1991, and September 30, 2001. Of the fund, $110 million went to third-party insurance payers and $40 million to individual consumers.⁵ Judge Richard G. Stearns granted final approval in May 2005.⁴ The claim window has long since closed.

Personal Injury Suits: What Patients Have Claimed

A separate line of litigation involves patients who took Lupron and later developed serious health problems. Reported adverse effects driving these suits include debilitating bone loss, chronic joint and muscle pain, memory problems, depression, suicidal thoughts, convulsions, and vision loss.⁶ A 2026 study of the FDA Adverse Event Reporting System from 2004 through the third quarter of 2024 counted 64,324 adverse event reports for leuprolide and 9,868 reported deaths.⁷

The FDA has repeatedly strengthened the drug’s label. Between 2010 and 2013, warnings were added for thromboembolism, bone density loss, and convulsions. In May 2017, warnings about psychiatric events and convulsions were added to the pediatric label.⁶ In September 2025, the FDA added warnings about severe cutaneous adverse reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis.⁸ The current label also warns of heart attack, stroke, diabetes, pituitary apoplexy, serious liver injury, and bone mineral density loss that may not be fully reversible.⁹

Why the Injury Cases Have Struggled

Despite the volume of adverse event reports, the two most prominent personal injury cases both ended in defeat for the patients.

The Klein Defense Verdict

The first Lupron personal injury case to reach trial was Klein v. TAP Pharmaceutical Products, Inc. and Abbott Laboratories, tried in federal court in Las Vegas in August 2011. Karin Klein was prescribed Lupron Depot 3.75 mg at age 17 and alleged the drug left her permanently disabled. She brought failure-to-warn claims and sought compensatory and punitive damages. The judge threw out the punitive damages claim as a matter of law, and the jury returned a unanimous defense verdict on the rest.¹⁰

The Ninth Circuit affirmed in May 2013. It upheld the trial judge’s exclusion of Lupron labels for other formulations, FDA adverse event reports (as unreliable hearsay), scientific articles (also hearsay), and supplemental expert reports filed years past the deadline. The court also rejected a claim of judicial bias, saying Klein had “not even remotely established” it.¹¹

Paulsen and the Statute of Limitations Trap

Paulsen v. Abbott Laboratories shows the other obstacle plaintiffs face: waiting too long. Terry Paulsen received two Lupron injections in 2004, developed bone and joint pain and memory loss, but did not sue until 2010. That initial case was dismissed in 2013 for failure to prosecute; when she refiled in 2015, courts flagged service problems and pleading deficiencies.¹²¹³

In July 2022, the Seventh Circuit affirmed dismissal on statute of limitations grounds. Applying Illinois’s two-year limit, the court found that Paulsen had known about her injuries and their suspected connection to Lupron for years before filing. The record included letters she wrote to her doctors in 2007 and 2008 blaming Lupron, medical records from 2004 through 2006 documenting the same belief, and an FDA adverse event report her mother filed in 2007. Her strict liability claim was separately barred by Georgia’s ten-year statute of repose.¹² For anyone considering a Lupron injury suit, that timing question is often the first hurdle.

Who You Sue Now

The corporate line behind Lupron matters because the original manufacturer no longer exists. TAP Pharmaceutical Products, the Abbott-Takeda joint venture, ended in April 2008, and TAP was merged into a Takeda subsidiary before being dissolved as a corporation in 2011. Abbott acquired the Lupron business, then spun its pharmaceutical operations off into AbbVie Inc. in 2012, and AbbVie took on TAP’s Lupron-related liabilities. Courts have dismissed claims against defunct entities like TAP for lack of corporate existence while allowing claims to proceed against Abbott and AbbVie.¹³ By 2017, Lupron was generating $829 million in annual sales for AbbVie.¹⁴

The Texas Puberty-Blocker Investigation

One additional matter is worth noting because it involves Lupron but is not a patient injury case. In December 2021, Texas Attorney General Ken Paxton opened an investigation into AbbVie and Endo Pharmaceuticals under the Texas Deceptive Trade Practices Act, focused on the promotion of puberty-blocking drugs, including Lupron, for treatment of gender dysphoria in minors, a use not approved by the FDA.¹⁵ Civil Investigative Demands went out in March 2022.¹⁶ No enforcement action, settlement, or further outcome has been publicly reported.

1
U.S. Department of Justice. TAP Pharmaceutical Products Inc. Settlement
2
Law.com. TAP Pharmaceutical Settles Lupron Civil Lawsuits
3
Phillips & Cohen LLP. TAP Pharmaceuticals Whistleblower Case Settles for $875 Million
4
Community Catalyst. Lupron Settlement Final Approval Order
5
U.S. District Court for the District of Massachusetts. Lupron Cy Pres Distribution Order
6
KTNV. More Women Come Forward With Complaints About Lupron Side Effects
7
Medicine (LWW). Evaluation of Adverse Event Profiles for Leuprolide and Goserelin
8
U.S. Food and Drug Administration. Lupron Depot 3.75 mg Prescribing Information
9
U.S. Food and Drug Administration. Lupron Depot Prescribing Information
10
Jones & Day. Abbott Wins Defense Verdict in First Pharmaceutical Products Liability Trial Involving Lupron
11
U.S. Court of Appeals for the Ninth Circuit. Klein v. TAP Pharmaceutical Products, Case No. 11-17250
12
FindLaw. Paulsen v. Abbott Laboratories, No. 21-2877
13
CaseMine. Paulsen v. Abbott Labs., March 2018 Order
14
WSB-TV. Georgia Woman Says Drug Used to Treat Endometriosis Led to Series of Health Problems
15
Texas Attorney General. AG Paxton to Investigate Promotion of Puberty Blockers for Children
16
Texas Attorney General. AG Paxton Investigates Potential Violations of State Law by Puberty-Blocking Drug Manufacturers